Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing
Grzegorzewski J, Bartsch F, Köller A, König M
Frontiers in pharmacology · 74 citas
Cómo se estudió
- Diseño
- Revisión sistemática (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Deutsche Forschungsgemeinschaft
- Gobierno
- Bundesministerium für Bildung und Forschung
- Universidad u hospital
- Humboldt-Universität zu Berlin
- Gobierno
- German Network for Bioinformatics Infrastructure
- Subvenciones
- German Network for Bioinformatics Infrastructure (031A533A); German Network for Bioinformatics Infrastructure (031A534A); German Network for Bioinformatics Infrastructure (031A538A); German Network for Bioinformatics Infrastructure (031 A535 A); Bundesministerium für Bildung und Forschung (031 A 534A); Bundesministerium für Bildung und Forschung (031A533A); Bundesministerium für Bildung und Forschung (031 A538A); Deutsche Forschungsgemeinschaft (031A533B); Deutsche Forschungsgemeinschaft (031A537C); German Network for Bioinformatics Infrastructure (031 A537B); Bundesministerium für Bildung und Forschung (# 031A537C); German Network for Bioinformatics Infrastructure (031A537B, 031A533A, 031A538A, 031A533B, 031A535A, 031A537C, 031A534A, 031A532B); Bundesministerium für Bildung und Forschung (031 A535A); Deutsche Forschungsgemeinschaft (031A534A); Bundesministerium für Bildung und Forschung (#031A537B); Bundesministerium für Bildung und Forschung (031A537B, 031A533A, 031A538A, 031A533B, 031A535A, 031A537C, 031A534A, 031A532B); German Network for Bioinformatics Infrastructure (031 A532B); German Network for Bioinformatics Infrastructure (031 A533B); Deutsche Forschungsgemeinschaft (031A537B); German Network for Bioinformatics Infrastructure (#031A537C); Deutsche Forschungsgemeinschaft (FOR 5151); Deutsche Forschungsgemeinschaft (031A535A); Deutsche Forschungsgemeinschaft (031A538A); Deutsche Forschungsgemeinschaft (031A532B); Bundesministerium für Bildung und Forschung (031A532B); Deutsche Forschungsgemeinschaft (031A533A); Bundesministerium für Bildung und Forschung (031L0054); Bundesministerium für Bildung und Forschung (031A533B)
Según 4 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2022-02-25 · Front Pharmacol · vol. 12 · pág. 752826
- Editorial
- Frontiers Media
- Citado
- 104 citas · más que el 99% de estudios similares · 12.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 196 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Coffee research and impacts · Pharmacogenetics and Drug Metabolism · Tea Polyphenols and Effects
- Palabras clave
- Caffeine, Paraxanthine, CYP1A2, Pharmacokinetics, Theobromine, Theophylline, Pharmacology, Context (archaeology), Physiologically based pharmacokinetic modelling, Medicine, Drug, Cytochrome P450, Biology, Internal medicine, Metabolism
4 autores
- Jan Grzegorzewski🇩🇪Humboldt-Universität zu Berlin
- Florian Bartsch🇩🇪Humboldt-Universität zu Berlin
- Adrian Köller🇩🇪Humboldt-Universität zu Berlin
- Matthias König🇩🇪Humboldt-Universität zu Berlin
Resumen
El texto original del estudio, en el idioma en que se publicó.
Caffeine is by far the most ubiquitous psychostimulant worldwide found in tea, coffee, cocoa, energy drinks, and many other beverages and food. Caffeine is almost exclusively metabolized in the liver by the cytochrome P-450 enzyme system to the main product paraxanthine and the additional products theobromine and theophylline. Besides its stimulating properties, two important applications of caffeine are metabolic phenotyping of cytochrome P450 1A2 (CYP1A2) and liver function testing. An open challenge in this context is to identify underlying causes of the large inter-individual variability in caffeine pharmacokinetics. Data is urgently needed to understand and quantify confounding factors such as lifestyle (e.g., smoking), the effects of drug-caffeine interactions (e.g., medication metabolized via CYP1A2), and the effect of disease. Here we report the first integrative and systematic analysis of data on caffeine pharmacokinetics from 141 publications and provide a comprehensive high-quality data set on the pharmacokinetics of caffeine, caffeine metabolites, and their metabolic ratios in human adults. The data set is enriched by meta-data on the characteristics of studied patient cohorts and subjects (e.g., age, body weight, smoking status, health status), the applied interventions (e.g., dosing, substance, route of application), measured pharmacokinetic time-courses, and pharmacokinetic parameters (e.g., clearance, half-life, area under the curve). We demonstrate via multiple applications how the data set can be used to solidify existing knowledge and gain new insights relevant for metabolic phenotyping and liver function testing based on caffeine. Specifically, we analyzed 1) the alteration of caffeine pharmacokinetics with smoking and use of oral contraceptives; 2) drug-drug interactions with caffeine as possible confounding factors of caffeine pharmacokinetics or source of adverse effects; 3) alteration of caffeine pharmacokinetics in disease; and 4) the applicability of caffeine as a salivary test substance by comparison of plasma and saliva data. In conclusion, our data set and analyses provide important resources which could enable more accurate caffeine-based metabolic phenotyping and liver function testing.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.